2. Epigenetics Apoptosis NF-κB
  3. Histone Acetyltransferase MDM-2/p53 NF-κB
  4. CBL0137

CBL0137  (Synonyms: Curaxin 137; CBL-C137)

製品番号: HY-18935 純度: 99.73%
COA 取扱説明書 Technical Support

CBL0137, a curaxin compound, is a histone chaperone facilitates chromatin transcription (FACT) inhibitor. CBL0137 downregulates NF-κB and activates p53. CBL0137 restores both histone H3 acetylation and trimethylation. CBL0137 is an anticancer agent. CBL0137 induces cancer cell apoptosis.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 1197996-80-7

容量 価格（税別） 在庫状況 数量
>無料サンプル (0.1 - 0.2 mg)   今すぐ申し込む  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 181 在庫あり
Solution
10 mM * 1 mL in DMSO USD 181 在庫あり
Solid
2 mg $77 在庫あり
5 mg $165 在庫あり
10 mg $264 在庫あり
25 mg $528 在庫あり
50 mg $730 在庫あり
100 mg $950 在庫あり
200 mg   お問い合わせ  
500 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 11 publication(s) in Google Scholar

Other Forms of CBL0137:

CBL0137 関連抗体

Top Publications Citing Use of Products

    CBL0137 purchased from MedChemExpress. Usage Cited in: Nano Today. 2025 Oct.

    Confocal fluorescence images and quantitative analysis of ZBP1 expression in RAW264.7 cells treated with HA@BPSN, free CBL0137, and CBL@BPSN for 24 hours.

    CBL0137 purchased from MedChemExpress. Usage Cited in: Nano Today. 2025 Oct.

    Raw264.7 cells treated with BPSN, CBL@BPSN, HA@BPSN, and free CBL0137 (24 h). Extraction of total RNA and assessment of relative mRNA levels of the indicated cytokine and chemokine genes using qRT-PCR.

    CBL0137 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2025 Oct 27;22(1):243.  [Abstract]

    CBL0137 (CBL) reduces HSV-1 replication in BMDMs. BMDMs were either mock-infected or infected with HSV-1 (MOI = 10) and treated with or without CBL (1 μM) 2 h post-infection. Virus DNA was measured by qPCR 6 h after infection. Each point represents an independent experiment.

    CBL0137 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2025 Oct 27;22(1):243.  [Abstract]

    CBL0137 (1 μM, 2 h) induced BMDM death during HSV-1 infection. Left: representative image of live cells (Calcein-AM, green) and dead cells (PI, red). Scale bar: 50 μm. Right: quantification of PI⁺ cells. Each dot represents an independent experiment (n = 3).

    CBL0137 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2025 Oct 27;22(1):243.  [Abstract]

    CBL0137 defends against HSV-1 retinal infection. Mice were IVT injected with PBS (CTRL) or HSV-1(4×10⁴ PFU). CBL0137 (2 μg, administered intravitreally) or PBS (mock) was co-injected with HSV-1.HE staining showing eye morphology. CBL preserved retinal structure in both WT and STING-/- mice following HSV-1 infection and prevented retinal necrosis in STING-/- mice at 9 dpi. Scale bars: overview 1 mm; magnified 100 μm.

    CBL0137 purchased from MedChemExpress. Usage Cited in: Cell. 2024 Dec 26;187(26):7533-7550.e23.  [Abstract]

    ALI organoid cultures were treated with CBL0137 hydrochloride (5 μM; 16 h) during homeostasis. Z-NA expression was assessed by immunofluorescence.

    CBL0137 purchased from MedChemExpress. Usage Cited in: Cell. 2024 Dec 26;187(26):7533-7550.e23.  [Abstract]

    DNA dot blot from ALI cultures (homeostasis), small intestine (ex vivo), or spheroids left untreated (NT) or treated with CBL0137 hydrochloride (5 μM; 16 h).

    CBL0137 purchased from MedChemExpress. Usage Cited in: Adv Mater. 2024 Jul;36(29):e2313991.  [Abstract]

    CBL0137 hydrochloride (5 μM; 8 h) remarkably facilitated Z-DNA formation in HCT116 cells.

    CBL0137 purchased from MedChemExpress. Usage Cited in: Adv Mater. 2024 Jul;36(29):e2313991.  [Abstract]

    CBL0137 hydrochloride (5 μM; 8 h) remarkably facilitated Z-DNA formation in four human tumor cells (HCT116, A549, MDA-MB-231; HeLa).

    CBL0137 purchased from MedChemExpress. Usage Cited in: Adv Mater. 2024 Jul;36(29):e2313991.  [Abstract]

    Long comet tail in the CBL0137 hydrochloride (5 μM; 8 h) treatment group was observed.

    CBL0137 purchased from MedChemExpress. Usage Cited in: Oncogene. 2023 Jan;42(1):11-25.  [Abstract]

    CBL0137 (1 μM) substantiality reduces cell proliferation and induces cell apoptosis (Ki67 for proliferation and cleaved-caspase3 (CC3) for apoptosis) in two EwS lines (A-673 and SK-N-MC cells).

    Histone Acetyltransferase アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    CBP/p300 GCN5/PCAF TIP60 MOZ/MORF HBO1

    NF-κB アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

    • 生物活性

    • プロトコル

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    CBL0137, a curaxin compound, is a histone chaperone facilitates chromatin transcription (FACT) inhibitor. CBL0137 downregulates NF-κB and activates p53. CBL0137 restores both histone H3 acetylation and trimethylation. CBL0137 is an anticancer agent. CBL0137 induces cancer cell apoptosis[1].

    体外実験

    Treatment with CBL-0137 leads to complete absence of living cells at concentrations above 2.5 μM. CBL-0137 causes a greater reduction in the number of colonies formed of not only MiaPaCa-2 cells when combined with Gemcitabine (HY-17026), but also Gemcitabine-resistant PANC-1 cells. Treatment of human pancreatic cancer cells with CBL-0137 results in a dose dependent reduction of protein and mRNA levels of RRM1 and RRM2. CBL-0137 is able to prevent Gemcitabine induced expression of RRM1 and RRM2 on mRNA and protein levels[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    CBL0137 関連抗体
    体内実験

    The CBL-0137 monotherapy group and the CBL-0137-Gemcitabine combination group samples show large necrotic fields, numerous apoptotic bodies and loss of tumor cells. Sub-optimal doses of 50 to 60 mg/kg CBL-0137 causes similar enhancement of Gemcitabine antitumor activity as that produced by the maximum tolerated dose (MTD) of 90 mg/kg as indicated by the lack of statistically significant differences among the combination groups. CBL0137 inhibits FACT function through depletion of the pool of active FACT involved in transcription elongation[1].
    CBL-0137, given by oral gavage at a nontoxic dose of 30 mg/kg per day on a 5 days on/2 days off schedule, suppresses tumor growth in xenografts of colon (DLD-1), renal cell carcinoma (Caki-1), and melanoma (Mel-7) tumor cell lines and transplanted surgical samples from patients with pancreatic ductal adenocarcinoma[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    臨床実験
    分子量

    336.43

    分子式

    C21H24N2O2
    CAS 番号
    Appearance

    Solid

    Color

    White to light yellow

    SMILES

    CC(NCCN1C2=C(C3=C1C=CC(C(C)=O)=C3)C=C(C(C)=O)C=C2)C
    輸送条件

    Room temperature in continental US; may vary elsewhere.
    保管条件

    4°C, sealed storage, away from moisture

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
    溶剤 & 溶解度
    体外: 

    DMSO : 11.11 mg/mL (33.02 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.9724 mL 14.8619 mL 29.7239 mL
    5 mM 0.5945 mL 2.9724 mL 5.9448 mL
    10 mM 0.2972 mL 1.4862 mL 2.9724 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始）

    C1

    ×
    体積 （開始）

    V1

    =
    濃度 （終了）

    C2

    ×
    体積 （終了）

    V2

    体内:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 1.11 mg/mL (3.30 mM); Clear solution

      This protocol yields a clear solution of ≥ 1.11 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (11.1 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 1.11 mg/mL (3.30 mM); Clear solution

      This protocol yields a clear solution of ≥ 1.11 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (11.1 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    純度とドキュメンテーション

    純度: 99.73%

    COA (253 KB) HNMR (258 KB) RP-HPLC (261 KB) MS (229 KB)

    取扱説明書 (2659 KB)
    参考文献
    キナーゼ実験
    [1]

    MiaPaca2 and BxPC-3 cells are treated with CBL-0137for 4 or 24h. Cells are harvested in 1× Cell Culture Lysis Reagent containing protease and phosphatase inhibitors. Lysates 5 to 20 μg are separated on SDS-PAGE gels and transferred to PVDF membranes. Blots are probed with antibodies specific for SSRP1, SPT16, RRM1, and RRM2. GAPDH is used as a loading control. Proteins are visualized using ECL kit[1].

    MedChemExpress (MCE) はこれらの方法の精度を確認していません。 こちらは参照専用です。
    細胞実験
    [1]

    Cells are resuspended in serum free Dulbecco's Modified Eagle Medium (DMEM) and treated with different concentrations of CBL-0137 for 1h. After that 105 from each treatment condition are plated in 3 wells of 6-well plate in 2mL of serum-free DMEM/F12 medium supplemented with 0.4% BSA, 0.2×B27, 10 ng/mL recombinant EGF and containing 0.25% agarose. 103 cells from each treatment condition are plated in 3 wells of 6-well plate in regular FBS containing medium. Colonies are counted using inverted microscope 7 to 15 days after plating[1].

    MedChemExpress (MCE) はこれらの方法の精度を確認していません。 こちらは参照専用です。
    動物実験
    [1]

    10-week old female athymic nude mice (n=8 per treatment group) are deeply anesthetized with ketamine/xylazine. Using laparotomy, 2× 106 PANC-1 cells are inoculated into the tail of the pancreas of each mouse. Two weeks following inoculation (tumor presence confirmed by ultrasound), treatment commenced. The following regimens are used: 1) vehicles, 100mg/kg captisol i.v. and sterile water via gavage, 2) 50 to 90 mg/kg CBL-0137 in 100 mg/mL captisol i.v. delivered via tail vein once per week, 3) 10 to 20 mg/kg CBL-0137 p.o. via oral gavage, 5 days on/2 days off, 4). Tumor measurement is done with digital calipers. Tumor volume is calculated using the equation L×W2/2 where L is the longest dimension and W is the dimension perpendicular to W. Mice are followed until at least one tumor per mouse reached 1000 mm3 or 90 days from start of treatment, whichever comes first[1].

    MedChemExpress (MCE) はこれらの方法の精度を確認していません。 こちらは参照専用です。
    参考文献

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.9724 mL 14.8619 mL 29.7239 mL 74.3097 mL
    5 mM 0.5945 mL 2.9724 mL 5.9448 mL 14.8619 mL
    10 mM 0.2972 mL 1.4862 mL 2.9724 mL 7.4310 mL
    15 mM 0.1982 mL 0.9908 mL 1.9816 mL 4.9540 mL
    20 mM 0.1486 mL 0.7431 mL 1.4862 mL 3.7155 mL
    25 mM 0.1189 mL 0.5945 mL 1.1890 mL 2.9724 mL
    30 mM 0.0991 mL 0.4954 mL 0.9908 mL 2.4770 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    CBL0137 Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    CBL01371197996-80-7Curaxin 137 CBL-C137CBL 0137CBL-0137Curaxin137Curaxin-137Histone AcetyltransferaseMDM-2/p53NF-κBHATsHATNuclear factor-κBNuclear factor-kappaBsmall-cell lung canceranticancerpancreatic cancerFACTInhibitorinhibitorinhibit

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

    		  

    カスタマ需要量 *

    お名前 *

    		 

    タイトル

    メールアドレス *

    		 

    電話番号 *

    デパートメント

    		 

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

    		      

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    CBL0137
    製品番号:
    HY-18935
    数量:
    MCE 日本正規代理店:

    カスタマーレビュー

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    製品名

    		  

    Lot #

    お名前 *

    		 

    メールアドレス *

    電話番号 *

    		 

    部門 *

    組纖名 *

    		 

    国或いは地域 *

    備考

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.